WO2014016548A3 - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number
WO2014016548A3
WO2014016548A3 PCT/GB2013/000328 GB2013000328W WO2014016548A3 WO 2014016548 A3 WO2014016548 A3 WO 2014016548A3 GB 2013000328 W GB2013000328 W GB 2013000328W WO 2014016548 A3 WO2014016548 A3 WO 2014016548A3
Authority
WO
WIPO (PCT)
Prior art keywords
olodaterol
further active
pharmaceutical composition
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2013/000328
Other languages
English (en)
Other versions
WO2014016548A2 (fr
Inventor
Shrinivas Madhukar Purandare
Geena Malhotra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of WO2014016548A2 publication Critical patent/WO2014016548A2/fr
Publication of WO2014016548A3 publication Critical patent/WO2014016548A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques pour inhalation qui comprennent un ou plusieurs bronchodilatateurs et un corticostéroïde inhalé. Plus particulièrement, la présente invention porte sur des compositions pharmaceutiques comprenant de l'olodaterol, un corticostéroïde inhalé et/ou un agent anticholinergique. La présente invention porte également sur un procédé pour la préparation de la composition pharmaceutique et sur son utilisation dans le traitement et/ou la prévention d'une maladie respiratoire, inflammatoire ou obstructive des voies aériennes.
PCT/GB2013/000328 2012-07-27 2013-07-29 Composition pharmaceutique Ceased WO2014016548A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2161/MUM/2012 2012-07-27
IN2161MU2012 2012-07-27

Publications (2)

Publication Number Publication Date
WO2014016548A2 WO2014016548A2 (fr) 2014-01-30
WO2014016548A3 true WO2014016548A3 (fr) 2014-03-20

Family

ID=48949176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2013/000328 Ceased WO2014016548A2 (fr) 2012-07-27 2013-07-29 Composition pharmaceutique

Country Status (1)

Country Link
WO (1) WO2014016548A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193213A1 (fr) * 2014-06-18 2015-12-23 Boehringer Ingelheim Vetmedica Gmbh Antagonistes muscariniques et leurs combinaisons pour le traitement de maladie des voies respiratoires chez des chevaux
CN104546861A (zh) * 2015-01-13 2015-04-29 段希福 一种包含奥达特罗和环索奈德的药物组合物及其用途
CN112472689B (zh) 2015-12-04 2023-01-17 墨西哥氟石股份公司 药物组合物
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN109789131B (zh) * 2016-09-19 2022-08-26 墨西哥氟石股份公司 药物组合物
US20190290633A1 (en) * 2017-10-27 2019-09-26 Nephron Pharmaceuticals Corporation Tiotropium Inhalation Solution for Nebulization
WO2019142214A1 (fr) * 2018-01-19 2019-07-25 Cipla Limited Composition pharmaceutique comprenant du tiotropium destinée à être inhalée
CN110876724A (zh) * 2018-09-06 2020-03-13 天津金耀集团有限公司 依地酸盐恰当改变噻托溴铵奥达特罗喷雾剂表面张力的应用
CN110876722A (zh) * 2018-09-06 2020-03-13 天津金耀集团有限公司 一种含有表面活性剂的噻托溴铵奥达特罗喷雾剂
US20210220367A1 (en) * 2020-01-20 2021-07-22 Cai Gu Huang Inhalable formulation of a solution containing glycopyrrolate and olodaterol hydrochloride
CN115397417A (zh) * 2020-04-16 2022-11-25 广州谷森制药有限公司 含有噻托溴铵和奥达特罗的可吸入溶液制剂
CN115835885B (zh) * 2020-06-23 2025-02-07 广州谷森制药有限公司 包含奥达特罗和布地奈德的药物组合物的制备
CN114028364A (zh) * 2021-11-26 2022-02-11 南京华盖制药有限公司 一种奥达特罗吸入溶液
CN117679423A (zh) * 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物
WO2026158575A1 (fr) * 2025-01-24 2026-07-30 正大天晴药业集团股份有限公司 Composition pharmaceutique comprenant du budésonide, du bromure de tiotropium et de l'olodatérol et procédé de préparation associé

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102349A1 (fr) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh Combinaisons medicamenteuses contenant de la benzoxazine pour traiter des maladies des voies respiratoires
WO2008020056A2 (fr) * 2006-08-18 2008-02-21 Boehringer Ingelheim International Gmbh Formulation aérosol pour l'inhalation de bêta-agonistes
WO2008020057A1 (fr) * 2006-08-18 2008-02-21 Boehringer Ingelheim International Gmbh Formulation d'aérosol pour l'inhalation de bêta-agonistes
WO2009059893A1 (fr) * 2007-11-05 2009-05-14 Boehringer Ingelheim International Gmbh Hydrate cristallin de bêta-mimétique et son utilisation en tant que médicament
WO2011073231A1 (fr) * 2009-12-18 2011-06-23 Nycomed Gmbh Dérivés de 3,4,4a,10b-tétrahydro-1h-thiopyrano-[4,3-c]isoquinoline
WO2012110770A2 (fr) * 2011-02-17 2012-08-23 Cipla Limited Composition pharmaceutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239778A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
TWI389692B (zh) 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
US20070086957A1 (en) 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102349A1 (fr) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh Combinaisons medicamenteuses contenant de la benzoxazine pour traiter des maladies des voies respiratoires
WO2008020056A2 (fr) * 2006-08-18 2008-02-21 Boehringer Ingelheim International Gmbh Formulation aérosol pour l'inhalation de bêta-agonistes
WO2008020057A1 (fr) * 2006-08-18 2008-02-21 Boehringer Ingelheim International Gmbh Formulation d'aérosol pour l'inhalation de bêta-agonistes
WO2009059893A1 (fr) * 2007-11-05 2009-05-14 Boehringer Ingelheim International Gmbh Hydrate cristallin de bêta-mimétique et son utilisation en tant que médicament
WO2011073231A1 (fr) * 2009-12-18 2011-06-23 Nycomed Gmbh Dérivés de 3,4,4a,10b-tétrahydro-1h-thiopyrano-[4,3-c]isoquinoline
WO2012110770A2 (fr) * 2011-02-17 2012-08-23 Cipla Limited Composition pharmaceutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. CAZZOLA ET AL: "Pharmacology and Therapeutics of Bronchodilators", PHARMACOLOGICAL REVIEWS, vol. 64, no. 3, 18 May 2012 (2012-05-18), pages 450 - 504, XP055083801, DOI: 10.1124/pr.111.004580 *

Also Published As

Publication number Publication date
WO2014016548A2 (fr) 2014-01-30

Similar Documents

Publication Publication Date Title
WO2012110770A3 (fr) Composition pharmaceutique
WO2012016889A3 (fr) Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2013021199A3 (fr) Compositions pharmaceutiques
HK1203149A1 (en) Novel dosage form and formulation of abediterol
WO2014064410A8 (fr) Composition pharmaceutique
PH12017502087A1 (en) Tiotropium inhalation solution for nebulization
WO2013112959A8 (fr) Composés antifibrotiques et leurs utilisations
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
WO2013036610A3 (fr) Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires
WO2014007772A3 (fr) Compositions d'inhalation contenant du glucose anhydre
WO2014007770A3 (fr) Compositions d'inhalation comprenant un corticostéroïde et du sorbitol
MX2014002465A (es) Composiciones acuosas que comprenden arbekacina.
WO2014007781A3 (fr) Compositions d'inhalation
WO2011093818A3 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
WO2011113000A8 (fr) Compositions inédites contenant des esters et méthodes associées
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
WO2013153349A3 (fr) Composition pharmaceutique
MX2014001940A (es) Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal.
WO2011093812A3 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
WO2019098969A3 (fr) Compositions de poudre sèche à inhaler
MY191295A (en) Pharmaceutical composition containing budesonide and formoterol
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
WO2013109216A3 (fr) Préparation de formulations en poudre sèche comprenant du tiotropium
MX2012014342A (es) Preparacion de una sal de levalbuterol.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13747480

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13747480

Country of ref document: EP

Kind code of ref document: A2